CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant Escherichia coli of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1639-1649

  Matsumura, Yasufumi ^a   Johnson, James R ^b   Yamamoto, Masaki ^a   Nagao, Miki ^a   Tanaka, Michio ^a   Takakura, Shunji ^a   Ichiyama, Satoshi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Clonal genotypes; CTX M; E. coli; ESBLs; MLST

Indexed keywords

AMIKACIN; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 14; BETA LACTAMASE CTX M 27; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL DNA; BETA LACTAMASE; BETA-LACTAMASE CTX-M-14; CTX-M-27, E COLI; ESCHERICHIA COLI PROTEIN;

ALLELE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENETIC VARIABILITY; JAPAN; JAPANESE (PEOPLE); MOLECULAR EPIDEMIOLOGY; NONHUMAN; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; EPIDEMIC; ESCHERICHIA COLI INFECTIONS; GENETICS; GENOTYPE; HOSPITAL; HUMAN; MICROBIOLOGY; POLYMERASE CHAIN REACTION; SECRETION (PROCESS); SEROTYPE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CIPROFLOXACIN; CLUSTER ANALYSIS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; EPIDEMICS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; GENOTYPE; HOSPITALS; HUMANS; JAPAN; MOLECULAR EPIDEMIOLOGY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SEROGROUP;

EID: 84930519823     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv017     Document Type: Article

References (58)

1. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum β-lactamases. Clin Microbiol Infect 2008; 14 Suppl 1: 33-41.
2. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1-14.
3. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27: 543-74.
4. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273-81.
5. Matsumura Y, Yamamoto M, Nagao M et al. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-β-lactamase-producing Escherichia coli in Japan. J Antimicrob Chemother 2012; 67: 2612-20.
6. Johnson JR, Clermont O, Johnston B et al. Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131. J ClinMicrobiol 2014; 52: 1358-65.
7. Dahbi G, Mora A, López C et al. Emergence of new variants of ST131 clonal group among extraintestinal pathogenic Escherichia coli producing extended-spectrum b-lactamases. Int J Antimicrob Agents 2013; 42: 347-51.
8. Blanc V, Leflon-Guibout V, Blanco J et al. Prevalence of day-care centre children (France) with faecal CTX-M-producing Escherichia coli comprising O25b:H4 and O16:H5 ST131 strains. J Antimicrob Chemother 2014; 69: 1231-7.
9. Kudinha T, Johnson JR, Andrew SD et al. Distribution of phylogenetic groups, sequence type ST131, and virulence-associated traits among Escherichia coli isolates from men with pyelonephritis or cystitis and healthy controls. Clin Microbiol Infect 2013; 19: E173-80.
10. Matsumura Y, Yamamoto M, Nagao M et al. Association of fluoroquinolone resistance, virulence genes, and IncF plasmids with extendedspectrum- β-lactamase-producing Escherichia coli sequence type 131 (ST131) and ST405 clonal groups. Antimicrob Agents Chemother 2013; 57: 4736-42.
11. Blanco J, Mora A, Mamani R et al. Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics. J Clin Microbiol 2013; 51: 3358-67.
12. Johnson JR, Tchesnokova V, Johnston B et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013; 207: 919-28.
13. Colpan A, Johnston B, Porter S et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013; 57: 1256-65.
14. Banerjee R, Robicsek A, Kuskowski MA et al. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob Agents Chemother 2013; 57: 6385-8.
15. Peirano G, van der Bij AK, Freeman JL et al. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum b-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother 2014; 58: 3762-7.
16. Price LB, Johnson JR, Aziz M et al. The epidemic of extendedspectrum- β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio 2013; 4: e00377-13.
17. Shin J, Kim DH, Ko KS. Comparison of CTX-M-14- and CTX-M-15- producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia. J Infect 2011; 63: 39-47.
18. Peirano G, van der Bij AK, Gregson DB et al. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamaseproducing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol 2012; 50: 294-9.
19. CTX-M genes. J Antimicrob Chemother 2006; 57: 14-23.
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
21. Xu L, Ensor V, Gossain S et al. Rapid and simple detection of blaCTX-M genes by multiplex PCR assay. J Med Microbiol 2005; 54: 1183-7.
22. Saladin M, Cao VT, Lambert Tet al. Diversity of CTX-M b-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett 2002; 209: 161-8.
23. Briñas L, Zarazaga M, Sáenz Yet al. β-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob Agents Chemother 2002; 46: 3156-63.
24. Yagi T, Kurokawa H, Shibata N et al. A preliminary survey of extendedspectrum b-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000; 184: 53-6.
25. Dallenne C, Da Costa A, Decré D et al. Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010; 65: 490-5.
26. Bert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCRrestriction fragment length polymorphism. J Antimicrob Chemother 2002; 50: 11-8.
27. Lee S, Park YJ, Kim M et al. Prevalence of Ambler class A and D b-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 2005; 56: 122-7.
28. Pérez-Pérez F, Hanson N. Detection of plasmid-mediated AmpC b-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-62.
29. Johnson JR, Menard M, Johnston B et al. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009; 53: 2733-9.
30. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66: 4555-8.
31. Clermont O, Lavollay M, Vimont S et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008; 61: 1024-8.
32. Clermont O, Johnson JR, Menard M et al. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagn Microbiol Infect Dis 2007; 57: 129-36.
33. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
34. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains frompatients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000; 181: 261-72.
35. Dhara L, Tripathi A. Genetic and structural insights into plasmidmediated extended-spectrum β-lactamase activity of CTX-M and SHV variants among pathogenic Enterobacteriaceae infecting Indian patients. Int J Antimicrob Agents 2014; 43: 518-26.
36. Al-Agamy MH, Shibl AM, Hafez MM et al. Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: emergence of CTX-M-15-producing E. coli ST131. Ann Clin Microbiol Antimicrob 2014; 13: 4.
37. Ho WS, Balan G, Puthucheary S et al. Prevalence and characterization of multidrug-resistant and extended-spectrum b-lactamase-producing Escherichia coli from pediatric wards of a Malaysian hospital. Microb Drug Resist 2012; 18: 408-16.
38. Pitout JD, Church DL, Gregson DB et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother 2007; 51: 1281-6.
39. Chandramohan L, Revell PA. Prevalence and molecular characterization of extended-spectrum-β-lactamase-producing Enterobacteriaceae in a pediatric patient population. Antimicrob Agents Chemother 2012; 56: 4765-70.
40. Freeman JT, Williamson DA, Heffernan H et al. Comparative epidemiology of CTX-M-14 and CTX-M-15 producing Escherichia coli: association with distinct demographic groups in the community in New Zealand. Eur J Clin Microbiol Infect Dis 2012; 31: 2057-60.
41. Naseer U, Olsson-Liljequist BE, Woodford N et al. Multi-locus variable number of tandem repeat analysis for rapid and accurate typing of virulent multidrug resistant Escherichia coli clones. PLoS One 2012; 7: e41232.
42. Cao X, Cavaco LM, Lv Y et al. Molecular characterization and antimicrobial susceptibility testing of Escherichia coli isolates from patients with urinary tract infections in 20 Chinese hospitals. J Clin Microbiol 2011; 49: 2496-501.
43. Adler A, Gniadkowski M, Baraniak A et al. Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre. Clin Microbiol Infect 2012; 18: E497-505.
44. Yano H, Uemura M, Endo S et al. Molecular characteristics of extendedspectrum β-lactamases in clinical isolates from Escherichia coli at a Japanese tertiary hospital. PLoS One 2013; 8: e64359.
45. Micenková L, Sišková P, Bosák J et al. Characterization of human uropathogenic ESBL-producing Escherichia coli in the Czech Republic: spread of CTX-M-27-producing strains in a university hospital. Microb Drug Resist 2014; 20: 610-7.
46. Seiffert SN, Hilty M, Kronenberg A et al. Extended-spectrum cephalosporin-resistant Escherichia coli in community, specialized outpatient clinic and hospital settings in Switzerland. J Antimicrob Chemother 2013; 68: 2249-54.
47. Snow LC, Warner RG, Cheney T et al. Risk factors associated with extended spectrum b-lactamase Escherichia coli (CTX-M) on dairy farms in north west England and north Wales. Prev Vet Med 2012; 106: 225-34.
48. Harada K, Nakai Y, Kataoka Y. Mechanisms of resistance to cephalosporin and emergence of O25b-ST131 clone harboring CTX-M-27 b-lactamase in extraintestinal pathogenic Escherichia coli from dogs and cats in Japan. Microbiol Immunol 2012; 56: 480-5.
49. Zurfluh K, Hächler H, Nüesch-Inderbinen M et al. Characteristics of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae Isolates from rivers and lakes in Switzerland. Appl Environ Microbiol 2013; 79: 3021-6.
50. Tausova D, Dolejska M, Cizek A et al. Escherichia coli with extendedspectrum β-lactamase and plasmid-mediated quinolone resistance genes in great cormorants and mallards in Central Europe. J Antimicrob Chemother 2012; 67: 1103-7.
51. Matsumura Y, Yamamoto M, Higuchi T et al. Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamaseproducing E. coli in Japan. Int J Antimicrob Agents 2012; 40: 158-62.
52. Bonnet R, Recule C, Baraduc R et al. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother 2003; 52: 29-35.
53. CTX-M genes. FEMS Microbiol Lett 2004; 234: 201-7.
54. Vinué L, Sáenz Y, Marti{dotless}nez S et al. Prevalence and diversity of extendedspectrum β-lactamases in faecal Escherichia coli isolates from healthy humans in Spain. Clin Microbiol Infect 2009; 15: 954-7.
55. CTX-M-15 in Escherichia coli from the faeces of travellers returning to the United Kingdom. J Antimicrob Chemother 2011; 66: 1005-12.
56. Doumith M, Dhanji H, Ellington MJ et al. Characterization of plasmids encoding extended-spectrum β-lactamases and their addiction systems circulating among Escherichia coli clinical isolates in the UK. J Antimicrob Chemother 2012; 67: 878-85.
57. Cullik A, Pfeifer Y, Prager R et al. A novel IS26 structure surrounds blaCTX-M genes in different plasmids from German clinical Escherichia coli isolates. J Med Microbiol 2010; 59: 580-7.
58. Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother 2014; 58: 4997-5004.